Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer.
A persistent human papillomavirus (HPV) infection is considered causal and necessary for the continued growth of cervical cancer. Thus, vaccination against HPV represents a plausible approach to prevent and treat cervical cancer. A report in the current issue of the European Journal of Immunology describes a therapeutic HPV DNA vaccination strategy using the HPV-16 E7 antigen fused to the invariant chain to enhance the E7-specific CD8+ and CD4+ T cell immune responses, resulting in a potent anti-tumor effect against E7-expressing tumors. Continued exploration of HPV therapeutic DNA vaccines may lead to eventual clinical application.
Wu
T-C
TC
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. wutc@jhmi.edu
D017951:Antigen Presentation / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000276:immunology*
D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA